Navigation Links
OrthoAccel® Technologies, Inc. Announces Definitive Distribution Agreement in Italy
Date:11/21/2011

HOUSTON, Nov. 21, 2011 /PRNewswire/ -- OrthoAccel® Technologies, Inc. announced this week that it has finalized a distribution agreement with Micerium S.p.A. based in Avegno for exclusive distribution rights of the AcceleDent™ System in Italy.

The AcceleDent™ System is currently being sold outside the USA and was first introduced in the United Kingdom in October 2009.  The lightweight appliance, used to speed up the rate of orthodontic treatment, is intended for 20 minutes of daily use.  Patients simply bite down on the Mouthpiece to hold it in place, which allows freedom of the hands to engage in other routine, daily activities during the treatment session.  Patients have reported using the appliance while engaged in a variety of activities, including homework, watching television, reading and listening to music.

Mike Kaufman, Vice President of Marketing and Business Development for OrthoAccel® commented, "Micerium is the most recent addition to our growing network of European distributors.  Italy is a key international market for us and it bodes well that this market leader shares our philosophy and excitement for how AcceleDent™ can change orthodontic treatment."  AcceleDent™ was introduced to the Italian orthodontic community during the SIDO meeting in Rome November 11-13.  Dr. Ravindra Nanda reported on the recent results from a randomized, controlled clinical trial conducted at the University of Texas Health Science Center at San Antonio under the guidance of Dr. Dubravko Pavlin where AcceleDent™ demonstrated, with statistical significance, that tooth movement could be safely accelerated by 38% to 50% during space closure and even more so during the alignment phase.

This definitive distribution agreement between OrthoAccel® and Micerium formalizes the intent to partner together that was initiated under a Terms of Agreement in June of this year.  Ottaviano Miceli, CEO of Micerium, expressed his enthusiasm, "I am excited about this new project. Our company has always paid attention to market innovations and we believe that AcceleDent is great news - a simple product that will bring many benefits to the orthodontic treatment in terms of time savings and results. In a short time we have already seen a great interest and desire to discover and try AcceleDent by the Italian orthodontists who want to offer the best treatment to their patients. " 

OrthoAccel® has been selling the AcceleDent™ System outside the USA since October 2009.  FDA clearance is pending based on an application submitted earlier this year.

About OrthoAccel® Technologies, Inc.
Based in Houston, Texas, OrthoAccel® Technologies, Inc. is a privately owned medical device company currently engaged in the development, manufacturing, and marketing of products to enhance dental care and orthodontic treatment.

About the
AcceleDent™ System
AcceleDent™
represents the first clinical approach to safely accelerate orthodontic tooth movement via modulating bone biology. The device has been studied clinically and applies gentle pulsing forces in combination with standard orthodontics to move teeth faster through accelerated bone remodeling. Importantly, the device works complementary with all existing orthodontic technologies. AcceleDent™ is neither FDA cleared nor FDA approved; it is currently investigational only in the United States. More information can be found at www.acceledent.com and www.acceledent.co.uk or requested via info@orthoaccel.com


'/>"/>
SOURCE OrthoAccel Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
2. Microchip Biotechnologies, Inc. Awarded Contract Under US Army Commercialization Pilot Program
3. JD Technologies, LLC Selected by FCT Ingenieurkeramik GmbH to Represent Their High Performance Ceramic Expertise In the United States
4. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q4/08 Review Issued by Scimitar Equity, LLC
5. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
6. Arbios Sells HepatAssist Bioartificial Liver System to HepaLife Technologies, Inc.
7. Advanced Analytical Technologies, Inc. Expands Into New Office and Production Space
8. AVAX Technologies, Inc. Announces Closing of Bridge Loan Financing
9. VNUS Medical Technologies, Inc. Announces the Hiring of Guido Smeets, MD, as Vice President of Clinical Research and Chief Medical Officer
10. Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results
11. GlaxoSmithKline Commences Tender Offer to Acquire Genelabs Technologies, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... , Australien, 28. Februar 2017 /PRNewswire/ ... innovatives Unternehmen, Anbieter und strategischer Partner des ... für den Gesundheitsbereich, das individuelle Gesundheitsversorgung fördert, ... Health Group (ITL) bekannt. ... einheitlichen Plans der neuen Markenidentität und wird ...
(Date:2/28/2017)... , Feb. 28, 2017 WuXi AppTec, ... open-access capability and technology platform company, today announced ... Shanghai once again passed ... observations. The inspectors from FDA thoroughly ... focusing on scientific data integrity, operation infrastructure, equipment, ...
(Date:2/28/2017)... ... February 28, 2017 , ... FireflySci is a small ... out in late 2014, FFS had a mission to bring affordable and quality lab ... another mega product that gives a lab everything needed to get started with using ...
(Date:2/28/2017)... (PRWEB) , ... February 28, 2017 , ... ... control solutions and services, announced today that it has joined the Cisco® Digital ... state-of-the-art Cisco technologies and provide hardware and software that addresses Industrial IT and ...
Breaking Biology Technology:
(Date:2/3/2017)... 2017 A new independent identity strategy consultancy ... (IdSP) . Designed to fill a critical niche in ... founding partners Mark Crego and Janice ... in identity expertise that span federal governments, the 9/11 ... Crego-Kephart combined expertise has a common theme born from ...
(Date:1/31/2017)... Mass. , Jan. 31, 2017  Spero ... novel therapies for the treatment of bacterial infections, ... set of antibacterial candidates from Pro Bono Bio ... increased prevalence of multi-drug resistant forms of Gram-negative ... Cantab Anti Infectives Ltd, a PBB group company. ...
(Date:1/24/2017)... YORK , Jan. 24, 2017 ... study of the laboratory use of nuclear magnetic ... 363 experienced end-users and profiled current practices, developments, ... years, as well as growth and opportunities. These ... Instrument suppliers, NMR instruments, needs and innovation requirements, ...
Breaking Biology News(10 mins):